Losartan, an angiotensin-II receptor-1 inhibitor, reduces TGF-β, CCN2, and ET-1 signaling in CAFs, improving drug and oxygen delivery in tumors and inhibiting mammary tumor development in mice. Here, TGFB1 is linked to breast cancer.